Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

MOTS-c Dosing: 1mg Daily, 5-On/2-Off Protocol (2026)

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you. Where These Numbers Come From MOTS-c was first identified by Changhan Lee and colleagues i

By Recovery & Performance Peptides Editorial Team

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

MOTS-c was first identified by Changhan Lee and colleagues in 2015 as a mitochondrial-encoded signaling peptide (Lee et al., 2015). The key findings driving current protocols:

AMPK activation mechanism: MOTS-c targets the methionine-folate cycle, raising cellular AICAR concentrations that activate AMPK. Under metabolic stress, MOTS-c translocates from the cytoplasm to the nucleus to regulate adaptive gene expression (Kim et al., 2018).

Late-life efficacy: MOTS-c treatment initiated at the mouse equivalent of ~70 human years improved physical capacity and healthspan with intermittent dosing (3x/week) (Lai et al., 2021).

Exercise mimetic context: MOTS-c activates overlapping pathways with exercise (AMPK, glucose uptake, fat oxidation) but does not replicate cardiovascular adaptation, bone loading, or neuromuscular development. It's best understood as a metabolic supplement to exercise, not a replacement.

Stacking Protocols

MOTS-c + SS-31

Dual mitochondrial approach

MOTS-c 1 mg + SS-31 500 mcg, both 5on/2off

MOTS-c + NAD+

Metabolic + energy substrate

MOTS-c 1 mg 5on/2off + NAD+ 100 mg 2-3x/week

MOTS-c and SS-31 work through completely different mechanisms — MOTS-c signals via AMPK while SS-31 physically stabilizes cardiolipin. See our SS-31 vs MOTS-c comparison for a detailed breakdown.

Side Effects & Safety

Injection site reactions — redness, mild pain, or swelling (more common with larger volumes)

Transient hypoglycemia-like symptoms — light-headedness or hunger if dosed fasted, reflecting glucose-lowering activity

Mild GI discomfort — nausea or stomach upset, typically first few days only

Mild flushing or warmth — occasional, transient

AMPK-mTOR trade-off — chronic AMPK activation may suppress muscle protein synthesis (rationale for cycling)

Drug interaction: metformin — both activate AMPK; additive glucose-lowering possible, and community protocols describe tracking blood glucose in this scenario.

Populations excluded from published trials: Type 1 diabetes subjects were excluded from MOTS-c research protocols (unpredictable glucose variability); no safety data exist for pregnant or breastfeeding subjects. Community sources describe heightened monitoring in both scenarios.

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once MOTS-c is reconstituted, the conversion from a target dose to syringe units depends on the chosen dilution.

The two reconstitution ratios most often described in community protocols are below.

Reconstitution A: 10 mg vial + 2 mL BAC water (5 mg/mL) — the standard dilution from the Quick Reference above.

0.5 mg

0.1 mL

10 units

1 mg

0.2 mL

20 units

1.5 mg

0.3 mL

30 units

2 mg

0.4 mL

40 units

Reconstitution B: 10 mg vial + 1 mL BAC water (10 mg/mL) — less BAC water for a lower total volume, so smaller draws and less fridge space.

0.05 mL

5 units

0.15 mL

15 units

These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.

Core Supplies for This Protocol

The three essentials for running any reconstituted injectable: cold storage, accurate syringes, and metabolic tracking.

Cooluli Classic 4L Mini Fridge

Compact thermoelectric mini-fridge with heat/cool toggle. The most-mentioned dedicated peptide-storage fridge in research community sources — fits ~20 vials and runs quietly.

BD Ultra-Fine 31G 0.3cc 5/16" Insulin Syringes (Box of 90)

0.3cc 31G syringes — each gradation marks 1 unit (vs 2 units on 1cc), making sub-50-unit peptide doses accurate. BD Ultra-Fine is the most widely-cited brand in peptide community sources.

CONTOUR NEXT GEN Glucose Meter All-In-One Kit

Ascensia's CONTOUR NEXT GEN — the most clinically-validated home glucose meter. Includes 20 test strips + lancing device. Tracks the blood-sugar response GLP-1 users care about, especially during dose escalation.

As an Amazon Associate, The Peptide Catalog earns from qualifying purchases.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Understanding Dosing Units: Milligrams (mg) vs. Micrograms (mcg)

This is a frequent point of confusion that can lead to significant errors. Let’s clear it up. The relationship is simple: 1 milligram (mg) = 1,000 micrograms (mcg) Most research protocols will refer to doses in milligrams (e.g., 5mg or 10mg). However, when you're drawing the solution into a syringe, you'll often be thinking in smaller units. It's essential to be comfortable with this conversion. For example, a 500mcg dose is the same as a 0.5mg dose. A simple decimal point error can result in a tenfold overdose or underdose, completely invalidating your research data. Double-check your math every single time.
02

Question drills

Open a question for its connected answer.

01What If MOTS-c Is Used in Combination With GLP-1 Receptor Agonists for Metabolic Research?+

Combine with caution and monitor glucose levels closely. Both compounds enhance insulin sensitivity through different mechanisms, potentially creating hypoglycemia risk in fasted states. MOTS-c increases glucose uptake via AMPK-mediated GLUT4 translocation (insulin-independent), while GLP-1 agonists enhance insulin secretion and slow gastric emptying (insulin-dependent). The combined effect may produce glucose disposal exceeding what either compound achieves alone. Preliminary data suggests the combination improves markers of metabolic flexibility more than monotherapy, but formal human trials examining safety and efficacy are lacking. Researchers exploring this combination often monitor continuous glucose levels throughout the dosing period to prevent hypoglycemic episodes.

SOURCE / realpeptides.co ↗
02What If I Miss a Scheduled MOTS-C Injection During a Training Week?+

The metabolic effects from a single dose persist 48–72 hours, so missing one injection in a 3x-weekly protocol doesn't create an immediate performance drop. You're working off residual AMPK activation and mitochondrial adaptations from prior doses. Resume the regular schedule with the next planned injection rather than doubling up to 'catch up.' MOTS-C doesn't function like an acute pre-workout stimulant where missing a dose means missing the effect entirely. The benefits accumulate through sustained signalling over weeks, not acute spikes. That said, consistency matters for maximising long-term mitochondrial biogenesis and metabolic flexibility, so treat missed doses as exceptions rather than routine.

SOURCE / realpeptides.co ↗
03What If the Research Protocol Requires Same-Day Dosing of Both Compounds?+

Administer MOTS-c first (fasted state), collect baseline metabolic samples at 60 and 120 minutes, then allow caffeine consumption after the 2-hour mark. This preserves the MOTS-c-specific response window for data collection while permitting caffeine later in the protocol when AMPK saturation no longer confounds the primary endpoints. Alternatively, dose caffeine in the evening (6+ hours post-MOTS-c) if the research design allows for separated metabolic windows.

SOURCE / realpeptides.co ↗
04What If a Subject Refuses Needles but Needs Precise Dosing?+

Intranasal spray is the only viable alternative, but you must increase the nominal dose by 3–4× and accept wider inter-subject variability. For example, if the protocol calls for 5mg subcutaneous daily, adjust to 15–20mg intranasal and monitor outcomes more closely across the cohort. Some subjects will still hit target metabolic endpoints despite lower plasma levels because MOTS-C exerts local effects in tissues adjacent to absorption sites before systemic distribution. Document the route change in protocol notes and consider measuring plasma MOTS-C levels at mid-protocol if precision matters for publication.

SOURCE / realpeptides.co ↗
05What If I Accidentally Inject MOTS-c After Eating Breakfast?+

The injection won't cause harm, but you've likely wasted most of that dose's metabolic benefit. Elevated insulin from the meal directly antagonizes AMPK activation. The primary pathway MOTS-c targets. You'll still get minor autophagy signaling and some mitochondrial communication, but metabolic studies show postprandial injections produce 60–70% lower AMPK phosphorylation compared to fasted-state dosing. Don't try to 'make up' the dose by injecting again later. Just count it as a learning experience and return to fasted morning timing for your next scheduled injection.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Why Reconstituting Degradation Matters for Research

The implications of achieving MOTS-c degradation reconstituted go far beyond mere academic curiosity. For researchers, it offers a powerful tool to: Identify Specific Enzymes: Pinpointing the exact proteases responsible for MOTS-c breakdown allows for targeted interventions. If you know the enzyme, you can develop inhibitors or activators. Determine Half-Life and Stability: Understanding how quickly MOTS-c is degraded helps predict its physiological half-life and guides the design of experiments where sustained or transient effects are desired. Uncover Regulatory Mechanisms: Degradation isn't random; it's often tightly regulated. Reconstituting the process can reveal cellular signals or conditions that either accelerate or decelerate MOTS-c turnover. Design Superior Analogs: With a clear picture of degradation, scientists can engineer MOTS-c analogs that are more stable, have a longer duration of action, or exhibit altered degradation profiles to suit specific research objectives. This is a critical, non-negotiable element for advancing peptide therapeutics. Model Disease States: Aberrant peptide degradation is implicated in numerous diseases. Reconstituting degradation in vitro can help model these pathological conditions and test potential therapeutic strategies. Our Mitochondrial Research initiatives frequently benefit from such detailed mechanistic studies. Honestly, though, the ability to observe MOTS-c degradation reconstituted with such clarity is a testament to the advancements in biochemical techniques over the past decade. It empowers researchers to move beyond correlative studies to truly mechanistic investigations, providing a deeper, more fundamental understanding of cellular processes. It's comprehensive.

RESEARCH

Beyond Metabolism: Fueling Cellular Energy and Longevity Research

While metabolic health is the headline act, the supporting cast of MOTS-c benefits is equally impressive, particularly in the realms of cellular energy and anti-aging research. Because MOTS-c originates from the mitochondria, it has a uniquely intimate relationship with these organelles. It functions as a mitohormetic signal, meaning it can induce a mild stress response in the mitochondria that ultimately makes them stronger and more efficient. Think of it like exercise for your cells. This process helps clear out damaged mitochondria (a process called mitophagy) and promotes the creation of new, healthy ones. This is a critical aspect of longevity science. As we age, mitochondrial function naturally declines. This decline is linked to a host of age-related conditions, from muscle wasting (sarcopenia) to cognitive decline. The potential for MOTS-c to rejuvenate mitochondrial populations is a cornerstone of its appeal. The MOTS-c benefits in this context are about preserving cellular vitality and resilience against the stressors of aging. For researchers focusing on this difficult, often moving-target objective, compounds that support mitochondrial health are paramount. Our team often recommends that labs studying cellular energy look into comprehensive approaches, such as our Energy, Mitochondria & Fatigue Elimination Bundle, to explore synergistic pathways. By enhancing the very foundation of cellular power production, the full scope of MOTS-c benefits extends far beyond simple glucose management. This is why we're so passionate about providing impeccably pure compounds for research. When you're studying something as fundamental as mitochondrial signaling, you can't afford to have impurities muddying the results. The integrity of the research depends on the integrity of the materials. We mean this sincerely: the future of this research runs on genuine connections between quality tools and brilliant minds. That’s the reality. It all comes down to reliability.

POTENTIAL BENEFITS

What Are the Key Benefits of Choosing Real Peptides in New York City?

Dependable access to mots-c 10mg for research use in New York City Transparent information about every mots c peptide product listed on our platform Consistent quality assurance backed by clear sourcing and professional standards Simple ordering process designed for busy researchers across the city Efficient shipping and fulfillment systems that keep projects on track Ongoing customer support to answer questions about ordering and availability Demand in New York City is higher than ever — secure your peptides now before stock runs low and others get ahead of you!
05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles